Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study.

William Townsend,Christian Buske,Guillaume Cartron,David Cunningham,Martin J. S. Dyer,John G. Gribben,Zilu Zhang,Kaspar Rufibach,Tina Nielsen,Michael Herold,Wolfgang Hiddemann,Robert Marcus

Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study.

2020

William Townsend
Christian Buske
Guillaume Cartron
David Cunningham
Martin J. S. Dyer
John G. Gribben
Zilu Zhang
Kaspar Rufibach
Tina Nielsen
Michael Herold
Wolfgang Hiddemann
Robert Marcus

8023Background: Immunochemotherapy is standard of care for patients (pts) with previously untreated advanced stage follicular lymphoma (FL). Four-year data from the Phase III GALLIUM study (NCT0133...

Keywords:

Oncology
Internal medicine
Chemotherapy
Rituximab
Pathology
in patient
Obinutuzumab
Medicine
Follicular lymphoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations